Get the app
US › Healthcare

Imunon Inc (IMNN)

US · Healthcare · Biotechnology

$1.02-3.77%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Net profit
$-2.8M
EPS
$-0.54
EPS estimate
$-0.94

EPS came in at -0.54 against a street estimate of -0.94 — a beat of 42.6%.

Key statistics

Market cap
$6.0M
Forward P/E
16.8
P/B
1.97
Book value
$0.41
EPS (TTM)
$-3.84
52-week high
$5.29
52-week low
$0.96
50-day MA
$1.48
200-day MA
$2.43
Beta
2.00

Analyst view

Analysts rate Imunon Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $17.00.

Shareholding

Insiders
6.06%
Institutions
5.68%

Largest institutional holders

FundStake
Armistice Capital, LLC2.58%
Vanguard Capital Management, LLC0.84%
Riverview Capital Advisers LLC0.61%
Geode Capital Management, LLC0.56%
Virtu Financial LLC0.31%
Vanguard Fiduciary Trust Co0.24%
Northern Trust Corp0.18%
UBS Group AG0.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Imunon Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.